Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

Inovio Pharmaceuticals, Inc. announced today that its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.

19 Apr 2013

North American scientists chart new territory in immunity research

Cracking the DNA code for a complex region of the human genome has helped 14 North American scientists, including five at Simon Fraser University, chart new territory in immunity research.

19 Apr 2013

Researchers find potential new genetic chemotherapy approach for cancer treatment

Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy.

18 Apr 2013

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

Researchers report progress on non-invasive method to assess kidney function

Researchers may have found a way to block kidney-destroying inflammation and help damaged kidney cells recover.

17 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

New approaches to treat persistent viral infections like HIV and hepatitis C

UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life.

10 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans.

9 Apr 2013

Antibody News and Research

Further Reading

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

North American scientists chart new territory in immunity research

Researchers find potential new genetic chemotherapy approach for cancer treatment

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Flunisyn Phase 2a trial data shows positive results in elderly population

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

Researchers report progress on non-invasive method to assess kidney function

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

New approaches to treat persistent viral infections like HIV and hepatitis C

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Data on PV-10 combination therapy presented at AACR Annual Meeting

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News